Teva, Novartis Settle Suit Over Generic Famvir

By Jocelyn Allison

Law360, New York (February 16, 2010, 1:35 PM ET) -- Israel-based Teva Pharmaceutical Industries Ltd.'s U.S. unit has settled a patent infringement suit brought by Novartis AG over a generic version of genital herpes drug Famvir.

Teva Pharmaceuticals USA Inc. will make a one-time payment to Novartis and pay ongoing royalties on future U.S. sales of the generic in exchange for a release from liability, Teva said.

No other terms were released, and a representative for Novartis could not immediately be reached for comment Tuesday. Settlement documents have not been filed in the case, which is...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles